Is the pill as good as the shot?
The pill has caught the first shot, not the best shot. Oral semaglutide, at about 11% of body weight lost, now matches Wegovy, the roughly 12% injection that opened the era. But the best injections stay well ahead and injection only: tirzepatide is about half again as much, at 18%, and retatrutide’s early Phase 3 topline points higher still, about 21%, not yet peer reviewed.
Where the oral-vs-injectable race stands, as of mid-2026.Three questions, not one
magnitude, tolerability, and the trade-offDoes it lose as much weight?
The one objective cross-route comparison. Weight lost is weight lost, whether from a pill or a shot, so both go on one scale.
Will you actually lose it?
Whether you can stay on the drug, and whether the headline number already counts the people who could not. How gentle it is depends on the drug, not on whether it is a pill.
Which should you pick?
A needle for a few more points, or a pill to skip the needle. That trade is yours to weigh, so it is the one we hand back to you.
Weight loss can be compared across routes. A grade cannot.
Q1 · On the scale
every drug, one shared magnitude axisEvery figure is placebo-adjusted (the drug’s result minus the placebo group’s) and counts everyone who started the drug, including those who stopped. That is the conservative estimand: Novo names it treatment policy, Lilly and Boehringer name it treatment regimen. The full method is on the methodology page.
Part molecule, part delivery
Not because pills are weak. The strongest weight loss today needs a multi-agonist peptide, and peptides are hard to absorb from the gut. The orals come in two kinds, and neither has closed the gap. The peptides pushed across the gut with an absorption enhancer, like oral semaglutide and oral amycretin, come with a strict empty-stomach routine and have topped out near 12% so far. The true small molecules, orforglipron and aleniglipron, have no such rule but are all single-target GLP-1 drugs.
Closing the gap needs an advance, not just time
The one thing that would put frontier efficacy in a clean pill, a small-molecule dual or triple, has no disclosed clinical candidate as of mid-2026. An unapproved 50 mg oral dose of semaglutide closes the gap to about parity in trials, but the board scores the approved 25 mg. So the pill catching the best shot is not a matter of waiting; it needs chemistry no one has shown yet.
Q2 · In real life
how well you tolerate it depends on the drugHow well you tolerate a drug depends on the drug, not on whether it is a pill or a shot. Oral semaglutide is one of the easiest here to stay on. Orforglipron, also a pill, is harder to tolerate than the Wegovy injection. So which pill you take matters more than the fact that it is a pill.
Q3 · For you
the one we will not scoreThe trade between a few more points of weight loss and never taking a needle is yours to weigh, so this is the question we hand back to you. Here is what differs once you have the numbers.
Most weight loss, needle and cold chain
Subcutaneous injection, once weekly. Storage: refrigerated (room temperature up to 28 days). The most weight loss, at the cost of an injection and keeping it cold.
Injection-class loss, a fasting routine
Oral pill, once daily, room temperature. The catch: must take fasting: empty stomach, limited water, wait before eating. No needle and no cold chain, but a daily routine you have to keep.
Fewest rules, less loss so far
Oral pill, once daily, no food or water rule, room temperature, and a scalable small-molecule supply. It trails the peptide pill on the scale; its case is convenience.
The specific head-to-heads: oral semaglutide vs orforglipron, orforglipron vs Wegovy, and the same molecule two ways, oral vs injectable semaglutide.
What would change the answer
what we are watching forThe answer changes when a pill finally matches an injection for weight loss on a schedule people can keep. The oral candidates chasing it are peptides: Amycretin and VK2735. Being oral peptides, they probably face the same absorption problem, though Viking has not disclosed an enhancer or a food rule for VK2735. The only true small molecule after orforglipron is aleniglipron, and it too is a single-target GLP-1 drug. The day one of them does, the answer here changes.